The global oncology market is set for remarkable expansion, projected to increase from $279.98 billion in 2026 to approximately $748.17 billion by 2035. This growth is largely driven by the transformative impact of immunotherapy on the treatment landscape for both solid tumors and hematologic cancers. Cancer drug revenues alone are anticipated to reach $335.2 billion by 2033, fueled by the swift adoption of targeted therapies, checkpoint inhibitors, and innovative cell therapies.
Immuno-Oncology Segment Surge
The immuno-oncology sector is expected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, with a compound annual growth rate (CAGR) of 14.9%. This growth reflects the increasing incidence of cancer and a surge in approvals for combination therapies. Immunotherapy continues to dominate oncology research and development, attracting unprecedented investment in checkpoint inhibitors, cancer vaccines, and cell therapies.
Breakthrough Trials in Colorectal Cancer
Oncolytics Biotech is initiating a pivotal study that may revolutionize treatment protocols for a particularly challenging form of colorectal cancer. The randomized Phase 2 trial, labeled REO 033, will assess the efficacy of pelareorep in conjunction with bevacizumab and FOLFIRI in patients with second-line RAS-mutated metastatic colorectal cancer. This demographic currently faces limited treatment options, and the need for innovative therapies is urgent.
Dr. Sanjay Goel from Rutgers Cancer Institute of New Jersey expresses enthusiasm for leading this study, citing the potential of pelareorep to significantly enhance patient outcomes. Previous findings from the REO 022 study support this optimism, demonstrating a marked improvement in overall survival and progression-free survival compared to existing treatments.
Compelling Clinical Data
The REO 033 trial’s foundation lies in prior compelling data, where pelareorep combined with bevacizumab and FOLFIRI yielded 27 months of overall survival and 16.6 months of progression-free survival, contrasting sharply with the 11.2 months and 5.7 months observed with standard care. The objective response rate of 33% significantly surpasses the approximately 10% achieved with conventional treatments, showcasing a potential breakthrough in this difficult-to-treat patient population.
Dr. Van Morris from The University of Texas MD Anderson Cancer Center highlights the importance of these findings, asserting that an effective immunotherapy could greatly enhance treatment options for colorectal cancer patients globally, especially as diagnoses rise.
Market Potential in Colorectal Cancer
The second-line treatment market for KRAS-mutant, microsatellite-stable metastatic colorectal cancer is estimated to be worth between $3-5 billion annually. In this context, Oncolytics Biotech will randomize 60 patients to receive either the pelareorep combination or a control regimen of bevacizumab and FOLFIRI, with the primary endpoint being the objective response rate. The first study site is set to open soon, with preliminary data expected by the end of 2026.
Expansion of Targeted Therapies
Eli Lilly has reported significant advancements in targeted therapies, particularly with Retevmo (selpercatinib) as an adjuvant treatment for early-stage RET fusion-positive lung cancer. The LIBRETTO-432 trial, which included 151 patients globally, has provided one of the largest datasets for adjuvant targeted therapy in this context. The findings reinforce the concept that early intervention can yield remarkable benefits in patient outcomes.
Lilly’s success is further underscored by the performance of their breast cancer therapeutic, Verzenio (abemaciclib), which achieved $5.3 billion in revenue for 2025, affirming Lilly’s leading position in targeted oncology therapeutics.
Strategic Acquisitions in Cell Therapy
In a significant move, Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, aiming to leverage the potential of anito-cel, a next-generation CAR-T cell therapy targeting relapsed or refractory multiple myeloma. The FDA’s acceptance of the anito-cel Biologics License Application (BLA) for review signifies a forthcoming addition to Gilead’s oncology portfolio, complementing Yescarta.
Gilead’s CEO, Daniel O’Day, emphasized the company’s commitment to accelerating development in this area, suggesting that anito-cel could become a cornerstone treatment for multiple myeloma.
Advancements in Bladder Cancer Treatment
Merck has presented new findings at the 2026 ASCO GU Cancers Symposium, demonstrating that Keytruda combined with Padcev significantly enhances event-free survival, overall survival, and pathologic complete response rates in muscle-invasive bladder cancer. These results further establish Merck’s leadership in the field of genitourinary oncology.
With over $31 billion in global sales in 2025, Keytruda remains the top-selling oncology drug worldwide. Merck continues to innovate, advancing clinical trials across major solid tumor types, including ongoing studies in colorectal and gastrointestinal cancers, where immunotherapy combinations show great promise.
Conclusion
The oncology market is witnessing dynamic changes fueled by innovative therapies and strategic acquisitions. With the rapid development of immunotherapy and targeted treatments, the future of cancer care is becoming increasingly hopeful. These advancements not only promise improved patient outcomes but also pave the way for a more robust and comprehensive approach to cancer treatment.
- Immunotherapy is reshaping cancer care, with significant market growth expected.
- Oncolytics Biotech’s REO 033 trial targets a challenging colorectal cancer population.
- Eli Lilly’s Retevmo shows promise in early-stage lung cancer treatment.
- Gilead’s acquisition of Arcellx highlights the increasing value of CAR-T therapies.
- Merck’s Keytruda continues to set records in oncology drug sales.
Read more → www.newswire.ca